Search bioRxiv⌕ Search

Biology subjects

Vural, O.

Publications and source records attributed to Vural, O..

2 recordsLinked to original sources

Calibration of AlphaGenome Variant Impact and SpliceAI2 scores as PP3/BP4 evidence for missense, non-coding, and synonymous variants

Computational predictions can serve as graded evidence in variant classification after calibration. We calibrated the AlphaGenome Variant Impact score (AVI) for missense variants and for six non-coding and synonymous classes, and SpliceAI2 for the six classes. For missense variants, AVI reached evidence between moderate and strong in both directions but did not outperform its component AlphaMissense. AVI reached strong pathogenic evidence in the three classes adjacent to exons. It reached moderate evidence, the highest estimable level, in proximal introns and at other synonymous sites, and supporting evidence, at an unstable threshold, in deep introns. SpliceAI2 reached the same levels, except one level lower at near-canonical positions and none in deep introns. No reached level failed validation on later ClinVar classifications, although 14 of 30 benign levels were not tested. With population variants as controls, both tools reached supporting and moderate pathogenic evidence in all six classes, at stricter thresholds near exons and at other synonymous sites, and at lower thresholds in proximal and deep introns. ClinVar likely benign classifications changed about 60-fold in number at 20 nucleotides from the exon without a change in measured splicing. AVI, a genome-wide score, did not differ detectably in discrimination from the splicing-specific SpliceAI2 in four classes; SpliceAI2 discriminated better in two classes and in a splicing assay, and was more sensitive at 99% specificity in four classes. Both scores provide calibrated evidence for non-coding and synonymous variants, but thresholds depend on whether ClinVar benign classifications or population variants are used for comparison.

genetics↗

Effects of 5-aza-2 -deoxycytidine on human osteoarthritic chondrocytes

BackgroundGiven regenerative therapies, the utilization of primary human cells is desired and requested in the development of in vitro systems and disease models. After a few passages in vitro, all cells from the connective tissue end up in a similar fibroblastoid cell type marked by loss of the specific expression pattern. It is still under discussion whether different de-differentiated mesenchymal cells have similar or identical differentiation capacities in vitro.\n\nMethodsChondrocytes isolated from patients with late-stage osteoarthritis were cultured for several passages until de-differentiation was completed. The mRNA level of cartilage markers was investigated, and the adipogenic, osteogenic and chondrogenic differentiation capacity was examined. By adding 5-aza-2-deoxycytidine (5-aza-dC) to the media, the influence of DNA methylation on the differentiation capacity was analyzed.\n\nResultsThe chondrocytes used in this work were not affected by the loss of specific gene expression upon cell culture. The mRNA levels of SOX5, SOX6, SOX9, aggrecan, and proteoglycan-4 remained unchanged. The underlying mechanisms of cartilage marker maintenance in osteoarthritic (OA) chondrocytes were investigated with a focus on the epigenetic modification by DNA methylation. The treatment of de-differentiated chondrocytes with the DNA methyltransferase inhibitor 5-aza-2-deoxycytidine (5-aza-dC) displayed no appreciable impact on the observed maintenance of marker gene expression, while the chondrogenic differentiation capacity was compromised. On the other hand, the pre-cultivation with 5-aza-dC improved the osteogenesis and adipogenesis of OA chondrocytes. Contradictory to these effects, the DNA methylation levels were not reduced after treatment with 1 M 5-aza-dC for four weeks.\n\nConclusionChondrocytes isolated from late-stage osteoarthritic patients represents a reliable cell source for in vitro studies as wells as disease models since the chondrogenic differentiation potential remains. 5-aza-2-deoxycytidine could not further improve their chondrogenic potential.

cell biology↗